These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23137122)

  • 1. Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease.
    Rosengart TK; Bishawi MM; Halbreiner MS; Fakhoury M; Finnin E; Hollmann C; Shroyer AL; Crystal RG
    Hum Gene Ther; 2013 Feb; 24(2):203-8. PubMed ID: 23137122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
    Rosengart TK; Lee LY; Patel SR; Sanborn TA; Parikh M; Bergman GW; Hachamovitch R; Szulc M; Kligfield PD; Okin PM; Hahn RT; Devereux RB; Post MR; Hackett NR; Foster T; Grasso TM; Lesser ML; Isom OW; Crystal RG
    Circulation; 1999 Aug; 100(5):468-74. PubMed ID: 10430759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.
    Rosengart TK; Lee LY; Patel SR; Kligfield PD; Okin PM; Hackett NR; Isom OW; Crystal RG
    Ann Surg; 1999 Oct; 230(4):466-70; discussion 470-2. PubMed ID: 10522716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.
    Stewart DJ; Hilton JD; Arnold JM; Gregoire J; Rivard A; Archer SL; Charbonneau F; Cohen E; Curtis M; Buller CE; Mendelsohn FO; Dib N; Page P; Ducas J; Plante S; Sullivan J; Macko J; Rasmussen C; Kessler PD; Rasmussen HS
    Gene Ther; 2006 Nov; 13(21):1503-11. PubMed ID: 16791287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up and safety assessment of angiogenic gene therapy trial VIF-CAD: Transcatheter intramyocardial administration of a bicistronic plasmid expressing VEGF-A165/bFGF cDNA for the treatment of refractory coronary artery disease.
    Kukuła K; Urbanowicz A; Kłopotowski M; Dąbrowski M; Pręgowski J; Kądziela J; Chmielak Z; Witkowski A; Rużyłło W
    Am Heart J; 2019 Sep; 215():78-82. PubMed ID: 31288177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease.
    Fuchs S; Dib N; Cohen BM; Okubagzi P; Diethrich EB; Campbell A; Macko J; Kessler PD; Rasmussen HS; Epstein SE; Kornowski R
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):372-8. PubMed ID: 16892433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of therapeutic angiogenesis from direct myocardial administration of an adenoviral vector expressing vascular endothelial growth factor 165.
    Zhang D; Gai L; Fan R; Dong W; Wen Y
    Chin Med J (Engl); 2002 May; 115(5):643-8. PubMed ID: 12133527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121.
    Lee LY; Patel SR; Hackett NR; Mack CA; Polce DR; El-Sawy T; Hachamovitch R; Zanzonico P; Sanborn TA; Parikh M; Isom OW; Crystal RG; Rosengart TK
    Ann Thorac Surg; 2000 Jan; 69(1):14-23; discussion 23-4. PubMed ID: 10654479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state.
    Schalch P; Rahman GF; Patejunas G; Goldschmidt RA; Carbray J; Retuerto MA; Kim D; Esser K; Crystal RG; Rosengart TK
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):535-40. PubMed ID: 14762365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats.
    Kaminsky SM; Quach L; Chen S; Pierre-Destine L; Van de Graaf B; Monette S; Rosenberg JB; De BP; Sondhi D; Hackett NR; Mezey JG; Rosengart TK; Crystal RG
    Hum Gene Ther Clin Dev; 2013 Mar; 24(1):38-46. PubMed ID: 23692382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
    Rajagopalan S; Mohler ER; Lederman RJ; Mendelsohn FO; Saucedo JF; Goldman CK; Blebea J; Macko J; Kessler PD; Rasmussen HS; Annex BH
    Circulation; 2003 Oct; 108(16):1933-8. PubMed ID: 14504183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial.
    Favaloro L; Diez M; Mendiz O; Janavel GV; Valdivieso L; Ratto R; Garelli G; Salmo F; Criscuolo M; Bercovich A; Crottogini A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):899-906. PubMed ID: 22777825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
    Ben-Gary H; McKinney RL; Rosengart T; Lesser ML; Crystal RG
    Mol Ther; 2002 Aug; 6(2):287-97. PubMed ID: 12349828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial.
    Kastrup J; Jørgensen E; Fuchs S; Nikol S; Bøtker HE; Gyöngyösi M; Glogar D; Kornowski R
    EuroIntervention; 2011 Feb; 6(7):813-8. PubMed ID: 21252014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.
    Losordo DW; Vale PR; Symes JF; Dunnington CH; Esakof DD; Maysky M; Ashare AB; Lathi K; Isner JM
    Circulation; 1998 Dec 22-29; 98(25):2800-4. PubMed ID: 9860779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations.
    Povsic TJ; Henry TD; Ohman EM; Pepine CJ; Crystal RG; Rosengart TK; Reinhardt RR; Dittrich HC; Traverse JH; Answini GA; Mokadam NA
    Am Heart J; 2021 Nov; 241():38-49. PubMed ID: 34224684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease.
    Huwer H; Welter C; Ozbek C; Seifert M; Straub U; Greilach P; Kalweit G; Isringhaus H
    Eur J Cardiothorac Surg; 2001 Dec; 20(6):1128-34. PubMed ID: 11717016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
    Symes JF; Losordo DW; Vale PR; Lathi KG; Esakof DD; Mayskiy M; Isner JM
    Ann Thorac Surg; 1999 Sep; 68(3):830-6; discussion 836-7. PubMed ID: 10509970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical use of intracoronary gene transfer of fibroblast growth factor for coronary artery disease.
    Penny WF; Hammond HK
    Curr Gene Ther; 2004 Jun; 4(2):225-30. PubMed ID: 15180588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication.
    Rajagopalan S; Trachtenberg J; Mohler E; Olin J; McBride S; Pak R; Rasmussen H; Crystal R
    Am J Cardiol; 2002 Sep; 90(5):512-6. PubMed ID: 12208412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.